“
“Reactive cement-in-polymer dispersions have been prepared from poly(vinyl alcohol), poly(ethylene-co-vinyl acetate), and poly(vinyl acetate) and a non-hydrated, fine-grained cement, and used to coat multifilament glass-rovings. The influence of the molecular properties of the polymer, such as the chemical composition and molecular weight CH5183284 solubility dmso as well as the cement content in the dispersion, on the reinforcing performance of the coated rovings in concrete has been studied using scanning electron microscopy and tensile tests. All coated rovings significantly surpass the uncoated glass in terms of mechanical behavior.

The best bonding was obtained with hydrophobic, PVAc-based coatings, since the slow hydrolysis and swelling of this polymer controls cement hydration and

the formation of the interphase. The mechanical behavior of the coated rovings is barely influenced by the molecular weight of the polymer, but decreases with decreasing cement content. (C) 2010 Wiley Periodicals, Inc. J Appl Polym Sci 116: 3303-3309, 2010″
“In ceramics of KTaO3. doped with 3 at. % of Mn the dielectric response is dominated by the polydispersive behavior of Mn2+ centered polar learn more regions, whereas the magnetic and magnetoelectric (ME) behaviors reflect an intimate coupling between A-site substituted Mn2+ ions and minute amounts of Mn3O4 precipitates mediated by the polar host material. This becomes apparent by the common onset at T-c approximate to 42 K of the ordering of ferrimagnetic Mn3O4 and of a spin cluster glass, which is characterized by memory and rejuvenation effects. The composite magnetic system exposed to external magnetic and electric dc fields shows large third order ME susceptibility with a sharp PI3K activation anomaly at T-c and 1/T-2 dependence as T -> 0. (C) 2010 American Institute of Physics. [doi: 10.1063/1.3430990]“
“ObjectiveA patient-centred approach to discussing life expectancy with cancer patients is recommended in Western countries. However, this approach to eliciting and

meeting patient preferences can be challenging for clinicians. The aims of this study were the following: (i) to examine cancer patients’ preferences for life expectancy disclosure; and (ii) to explore agreement between cancer patients’ preferences for, and perceived experiences of, life expectancy disclosure.

MethodsCancer patients undergoing radiotherapy treatment in metropolitan Australia completed a cross-sectional touchscreen computer survey including optional questions about their life expectancy disclosure preferences and experiences.

ResultsOf the 208 respondents, 178 (86%) indicated that they would prefer their clinician to ask them before discussing life expectancy, and 30 (14%) indicated that they would prefer others (i.e. clinicians, family) to decide whether they were given life expectancy information.